Abstract
Abstract
Background
In this paper we assess the quality of six deliberative stakeholder consultations regarding the implementation of a precision diagnostic for life-threatening pediatric brain tumors. Decision makers who base policy recommendations on the outputs of consultative exercises can presuppose that all deliberants are well informed of the policy issue, that participation in the deliberative process was fair, and that overcoming implementation barriers will necessarily result in practice change. Additional evidence is therefore needed to substantiate the informational quality of the deliberation, measure the equality of participation and study the effects on stakeholder reasoning to appropriately guide uptake of proposed recommendation(s).
Methods
Using the DeVries framework for assessing the deliberative quality, we analyzed data from 44 post-consultation evaluation surveys completed by pediatric oncology and palliative care teams at two tertiary pediatric healthcare centers in Canada. We also conducted turn-taking and word-contribution analyses from the text transcriptions of each deliberation to assess equality of participation using descriptive statistics.
Results
Deliberants agreed the quality of the deliberative process was fair (median ratings ranging from 9–10 out of 10) and the opportunities to receive expert information and discuss with others about the implementation of a new LDT were helpful (9.5 out of 10). While the session improved understanding of the implementation barriers and opportunities, it had marginal effects on deliberants’ reasoning about whether LDTs would change their own clinical practice (3–10 out of 10). Participation was proportionate in at least four of the six deliberations, where no deliberant took more than 20% of total turns and contributed equal to, or less than 20% of total words.
Conclusion
The quality assessment we performed demonstrates high informational value and perceived fairness of two deliberative stakeholder consultations involving pediatric palliative care and oncology teams in Canada. Quality assessments can reveal how the process of deliberation unfolds, whether deliberative outputs are the result of equitable participation among deliberants and what, if any, stakeholder voices may be missing. Such assessments should be routinely reported as a condition of methodological rigor and trustworthiness of deliberative stakeholder engagement research.
Funder
Genome Canada
Canadian Institutes of Health Research
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Jones DTW, Bandopadhayay P, Jabado N. The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. Annu Rev Genet. 2019;53:483–503.
2. Adel Fahmideh M, Lavebratt C, Tettamanti G, Schüz J, Röösli M, Kjaerheim K, et al. A Weighted Genetic Risk Score of Adult Glioma Susceptibility Loci Associated with Pediatric Brain Tumor Risk. Sci Rep. 2019;9:8–11.
3. Crimi L. Master’s Thesis. Barriers to Personalized Medicine in Pediatrics: The Implementation of A Novel Pharmacogenomic Test for Pediatric Neuroblastoma: McGill University; 2015.
4. Weaver SM, Heinze KE, Kelly KP, Wiener L, Casey RL, et al. Palliative Care as a Standard of Care in Pediatric Oncology. Pediatr Blood Cancer. 2015;62(Suppl 5):S829–33.
5. Cooley C, Adeodu S, Aldred H, Beesley S, Leung A, Thacker L. Paediatric palliative care: a lack of research-based evidence. Int J Palliat Care Nurs. 2013;6(7):346–51.